PTCH1 and medulloblastoma: The over-activating mechanisms that work through a non-canonical HH-GLI1 pathway (Figure 3A) have been used as targets for therapeutic strategies in epithelial BCC or medulloblastoma, both of which depend on genetic mutations of PTCH1 for activation, and as such may encounter successful inhibition with specific compounds (Figure 3B).